Use of serum insulin-like growth factor-I levels to predict psychiatric non-response to donepezil in patients with Alzheimer's disease

Eitetsu Tei, Hideki Yamamoto, Takuya Watanabe, Akira Miyazaki, Toshio Nakadate, Nobumasa Kato, Masaru Mimura

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Objective: Insulin-like growth factor-I (IGF-I) deficiency may be involved in cognitive deficits seen with aging and in neurodegenerative diseases such as Alzheimer's disease (AD). This study was aimed at investigating whether non-responder to donepezil could be predicted using decreased serum levels of IGF-I in AD patients. Design: This study involved 106 elderly subjects: 50 patients with AD and 56 age-matched controls without dementia. In patients with AD, donepezil was given orally 3 mg/day for 4 weeks and 5 mg/day for another 12 weeks. AD patients were divided into responders and non-responders based on the changes in mini-mental state examination (MMSE) scores before and 16 weeks after treatment with donepezil. Serum levels of IGF-I and atherogenic biomarkers were determined. Results: Before treatment with donepezil, there was a significant positive correlation between serum IGF-I levels and the MMSE scores in all subjects. Serum IGF-I levels and the MMSE scores were significantly lower in AD patients than in non-demented controls and were the lowest in non-responders to donepezil. Atherogenic biomarkers (LDL cholesterol, triglycerides, lipoprotein(a), lipid peroxide, apolipoprotein E, and glucose levels) did not differ significantly among these groups. On multiple logistic regression, non-responders to donepezil showed decreased serum IGF-I levels <110 ng/ml and MMSE scores <15 points before treatment. Conclusions: These findings suggest that decreased levels of serum IGF-I combined with MMSE scores before treatment could predict non-responders to donepezil among AD patients, which may be a simple and practical method for selecting patients expected to show a response to treatment.

Original languageEnglish
Pages (from-to)47-54
Number of pages8
JournalGrowth Hormone and IGF Research
Volume18
Issue number1
DOIs
Publication statusPublished - 2008 Feb
Externally publishedYes

Fingerprint

Insulin-Like Growth Factor I
Psychiatry
Alzheimer Disease
Serum
Biomarkers
Therapeutics
Lipoprotein(a)
Lipid Peroxides
Apolipoproteins E
donepezil
Neurodegenerative Diseases
LDL Cholesterol
Dementia
Logistic Models
Glucose

Keywords

  • Alzheimer's disease
  • Donepezil
  • Insulin-like growth factor-I
  • Mini-mental state examination

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Use of serum insulin-like growth factor-I levels to predict psychiatric non-response to donepezil in patients with Alzheimer's disease. / Tei, Eitetsu; Yamamoto, Hideki; Watanabe, Takuya; Miyazaki, Akira; Nakadate, Toshio; Kato, Nobumasa; Mimura, Masaru.

In: Growth Hormone and IGF Research, Vol. 18, No. 1, 02.2008, p. 47-54.

Research output: Contribution to journalArticle

Tei, Eitetsu ; Yamamoto, Hideki ; Watanabe, Takuya ; Miyazaki, Akira ; Nakadate, Toshio ; Kato, Nobumasa ; Mimura, Masaru. / Use of serum insulin-like growth factor-I levels to predict psychiatric non-response to donepezil in patients with Alzheimer's disease. In: Growth Hormone and IGF Research. 2008 ; Vol. 18, No. 1. pp. 47-54.
@article{59a199f118e7418c9617d7a7b20fce11,
title = "Use of serum insulin-like growth factor-I levels to predict psychiatric non-response to donepezil in patients with Alzheimer's disease",
abstract = "Objective: Insulin-like growth factor-I (IGF-I) deficiency may be involved in cognitive deficits seen with aging and in neurodegenerative diseases such as Alzheimer's disease (AD). This study was aimed at investigating whether non-responder to donepezil could be predicted using decreased serum levels of IGF-I in AD patients. Design: This study involved 106 elderly subjects: 50 patients with AD and 56 age-matched controls without dementia. In patients with AD, donepezil was given orally 3 mg/day for 4 weeks and 5 mg/day for another 12 weeks. AD patients were divided into responders and non-responders based on the changes in mini-mental state examination (MMSE) scores before and 16 weeks after treatment with donepezil. Serum levels of IGF-I and atherogenic biomarkers were determined. Results: Before treatment with donepezil, there was a significant positive correlation between serum IGF-I levels and the MMSE scores in all subjects. Serum IGF-I levels and the MMSE scores were significantly lower in AD patients than in non-demented controls and were the lowest in non-responders to donepezil. Atherogenic biomarkers (LDL cholesterol, triglycerides, lipoprotein(a), lipid peroxide, apolipoprotein E, and glucose levels) did not differ significantly among these groups. On multiple logistic regression, non-responders to donepezil showed decreased serum IGF-I levels <110 ng/ml and MMSE scores <15 points before treatment. Conclusions: These findings suggest that decreased levels of serum IGF-I combined with MMSE scores before treatment could predict non-responders to donepezil among AD patients, which may be a simple and practical method for selecting patients expected to show a response to treatment.",
keywords = "Alzheimer's disease, Donepezil, Insulin-like growth factor-I, Mini-mental state examination",
author = "Eitetsu Tei and Hideki Yamamoto and Takuya Watanabe and Akira Miyazaki and Toshio Nakadate and Nobumasa Kato and Masaru Mimura",
year = "2008",
month = "2",
doi = "10.1016/j.ghir.2007.07.006",
language = "English",
volume = "18",
pages = "47--54",
journal = "Endocrinology and Metabolism",
issn = "1096-6374",
publisher = "Churchill Livingstone",
number = "1",

}

TY - JOUR

T1 - Use of serum insulin-like growth factor-I levels to predict psychiatric non-response to donepezil in patients with Alzheimer's disease

AU - Tei, Eitetsu

AU - Yamamoto, Hideki

AU - Watanabe, Takuya

AU - Miyazaki, Akira

AU - Nakadate, Toshio

AU - Kato, Nobumasa

AU - Mimura, Masaru

PY - 2008/2

Y1 - 2008/2

N2 - Objective: Insulin-like growth factor-I (IGF-I) deficiency may be involved in cognitive deficits seen with aging and in neurodegenerative diseases such as Alzheimer's disease (AD). This study was aimed at investigating whether non-responder to donepezil could be predicted using decreased serum levels of IGF-I in AD patients. Design: This study involved 106 elderly subjects: 50 patients with AD and 56 age-matched controls without dementia. In patients with AD, donepezil was given orally 3 mg/day for 4 weeks and 5 mg/day for another 12 weeks. AD patients were divided into responders and non-responders based on the changes in mini-mental state examination (MMSE) scores before and 16 weeks after treatment with donepezil. Serum levels of IGF-I and atherogenic biomarkers were determined. Results: Before treatment with donepezil, there was a significant positive correlation between serum IGF-I levels and the MMSE scores in all subjects. Serum IGF-I levels and the MMSE scores were significantly lower in AD patients than in non-demented controls and were the lowest in non-responders to donepezil. Atherogenic biomarkers (LDL cholesterol, triglycerides, lipoprotein(a), lipid peroxide, apolipoprotein E, and glucose levels) did not differ significantly among these groups. On multiple logistic regression, non-responders to donepezil showed decreased serum IGF-I levels <110 ng/ml and MMSE scores <15 points before treatment. Conclusions: These findings suggest that decreased levels of serum IGF-I combined with MMSE scores before treatment could predict non-responders to donepezil among AD patients, which may be a simple and practical method for selecting patients expected to show a response to treatment.

AB - Objective: Insulin-like growth factor-I (IGF-I) deficiency may be involved in cognitive deficits seen with aging and in neurodegenerative diseases such as Alzheimer's disease (AD). This study was aimed at investigating whether non-responder to donepezil could be predicted using decreased serum levels of IGF-I in AD patients. Design: This study involved 106 elderly subjects: 50 patients with AD and 56 age-matched controls without dementia. In patients with AD, donepezil was given orally 3 mg/day for 4 weeks and 5 mg/day for another 12 weeks. AD patients were divided into responders and non-responders based on the changes in mini-mental state examination (MMSE) scores before and 16 weeks after treatment with donepezil. Serum levels of IGF-I and atherogenic biomarkers were determined. Results: Before treatment with donepezil, there was a significant positive correlation between serum IGF-I levels and the MMSE scores in all subjects. Serum IGF-I levels and the MMSE scores were significantly lower in AD patients than in non-demented controls and were the lowest in non-responders to donepezil. Atherogenic biomarkers (LDL cholesterol, triglycerides, lipoprotein(a), lipid peroxide, apolipoprotein E, and glucose levels) did not differ significantly among these groups. On multiple logistic regression, non-responders to donepezil showed decreased serum IGF-I levels <110 ng/ml and MMSE scores <15 points before treatment. Conclusions: These findings suggest that decreased levels of serum IGF-I combined with MMSE scores before treatment could predict non-responders to donepezil among AD patients, which may be a simple and practical method for selecting patients expected to show a response to treatment.

KW - Alzheimer's disease

KW - Donepezil

KW - Insulin-like growth factor-I

KW - Mini-mental state examination

UR - http://www.scopus.com/inward/record.url?scp=39049165846&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=39049165846&partnerID=8YFLogxK

U2 - 10.1016/j.ghir.2007.07.006

DO - 10.1016/j.ghir.2007.07.006

M3 - Article

C2 - 17714966

AN - SCOPUS:39049165846

VL - 18

SP - 47

EP - 54

JO - Endocrinology and Metabolism

JF - Endocrinology and Metabolism

SN - 1096-6374

IS - 1

ER -